Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes

International Journal of Molecular Medicine

Volumn 35, Issue 3, 2015, Pages 803-809

  Kang, Ok Hwa ^a   Kim, Sung Bae ^b   Mun, Su Hyun ^b   Seo, Yun Soo ^a   Hwang, Hyeong Chil ^a   Lee, Young Mi ^a   Lee, Ho Seob ^b   Kang, Dae Gil ^b   Kwon, Dong Yeul ^a  

^a Wonkwang University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Adenosine 5' monophosphate activated protein kinase; Hepatic lipogenesis; Lipid accumulation; Puerarin

Indexed keywords

ADENOSINE PHOSPHATE; ADENYLATE KINASE; CHOLESTEROL; FATTY ACID SYNTHASE; LIPID; MESSENGER RNA; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PUERARIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ISOFLAVONE DERIVATIVE;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FATTY LIVER; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY;

AMP-ACTIVATED PROTEIN KINASES; FATTY LIVER; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; ISOFLAVONES; LIPID METABOLISM; OLEIC ACID; PPAR ALPHA; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84921773663     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2074     Document Type: Article

References (39)

1. Zhang S, Ji G and Liu J: Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J Nutr Biochem 17: 485-491, 2006.
2. Yeung DK, Leung SW, Xu YC, Vanhoutte PM and Man RY: Puerarin, an isoflavonoid derived from Radix puerariae, potentiates endothelium-independent relaxation via the cyclic AMP pathway in porcine coronary artery. Eur J Pharmacol 552: 105-111, 2006.
3. Li Q, Xiao Y, Gong H, Shen D, Zhu F, Wu Q, Chen H and Zhong H: Effect of puerarin on the expression of extracellular matrix in rats with streptozotocin-induced diabetic nephropathy. Natl Med J India 22: 9-12, 2009.
4. Guerra MC, Speroni E, Broccoli M, Cangini M, Pasini P, Minghett A, Crespi-Perellino N, Mirasoli M, Cantelli-Forti G and Paolini M: Comparison between Chinese medical herb Pueraria lobata crude extract and its main isoflavone puerarin antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci 67: 2997-3006, 2000.
5. Yan LP, Chan SW, Chan AS, Chen SL, Ma XJ and Xu HX: Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci 79: 324-330, 2006.
6. Han RM, Tian YX, Becker EM, Andersen ML, Zhang JP and Skibsted LH: Puerarin and conjugate bases as radical scavengers and antioxidants: molecular mechanism and synergism with beta-carotene. J Agric Food Chem 55: 2384-2391, 2007.
7. Zhao M, Du YQ, Yuan L and Wang NN: Protective effect of puerarin on acute alcoholic liver injury. Am J Chin Med 38: 241-249, 2010.
8. Yang X, Hu W, Zhang Q, Wang Y and Sun L: Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol 107 : 637-642, 2010.
9. Kim KM, Jung DH, Jang DS, Kim YS, Kim JM, Kim HN, Surh YJ and Kim JS: Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression. Toxicol Appl Pharmacol 244: 106-113, 2010.
10. Zheng P, Ji G, Ma Z, Liu T, Xin L, Wu H, Liang X and Liu J: Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 37: 69-83, 2009.
11. Singh AK, Jiang Y, Benlhabib E and Gupta S: Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcoholrelated disorders in P rats receiving free choice water and 15% ethanol in pure water. J Med Food 10: 526-542, 2007.
12. Xiong FL, Sun XH, Gan L, Yang XL and Xu HB: Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. Eur J Pharmacol 529: 1-7, 2006.
13. Cheng YF, Zhu GQ, Wang M, Cheng H, Zhou A, Wang N, Fang N, Wang XC, Xiao XQ, Chen ZW and Li QL: Involvement of ubiquitin proteasome system in protective mechanisms of puerarin to MPP(+)-elicited apoptosis. Neurosci Res 63: 52-58, 2009.
14. Bo J, Ming BY, Gang LZ, Lei C and Jia AL: Protection by puerarin against MPP+ -induced neurotoxicity in PC12 cells mediated by inhibiting mitochondrial dysfunction and caspase-3-like activation. Neurosci Res 53: 183-188, 2005.
15. Xu X and Zheng X: Potential involvement of calcium and nitric oxide in protective effects of puerarin on oxygen-glucose deprivation in cultured hippocampal neurons. J Ethnopharmacol 113: 421-426, 2007.
16. Mercer LD, Kelly BL, Horne MK and Beart PM: Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem Pharmacol 69: 339-345, 2005.
17. Chung MJ, Sung NJ, Park CS, Kweon DK, Mantovani A, Moon TW, Lee SJ and Park KH: Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur J Pharmacol 578: 159-170, 2008.
18. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
19. American Gastroenterology Association: American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123: 1702-1704, 2002.
20. Koteish A and Diehl AM: Animal models of steatosis. Semin Liver Dis 21: 89-104, 2001.
21. Satia-Abouta J, Patterson RE, Schiller RN and Kristal AR: Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med 34: 493-501, 2002.
22. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S and Yamada N: Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274: 35832-35839, 1999.
23. Aggarwal BB: Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30: 173-199, 2010.
24. Brown MS and Goldstein JL: The SREBP pathway:regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997.
25. Berger JP, Akiyama TE and Meinke PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26: 244-251, 2005.
26. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
27. You M, Matsumoto M, Pacold CM, Cho WK and Crabb DW: The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127: 1798-1808, 2004.
28. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
29. Tsukamoto H, She H, Hazra S, Cheng J and Miyahara T: Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 21 (Suppl 3): S102-S105, 2006.
30. Kang OH, Kim SB, Seo YS, Joung DK, Mun SH, Choi JG, Lee YM, Kang DG, Lee HS and Kwon DY: Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur Rev Med Pharmacol Sci 17: 2578-2586, 2013.
31. Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG and Jin T: Puerarin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One 7: e28784, 2012.
32. Roche H, Zampelas A, Knapper JM, Webb D, Brooks C, Jackson KG, Wright JW, Gould BJ, Kafatos A, Gibney MJ and Williams CM: Effect of long-term olive oil dietary intervention on postprandial triacylglycerol and factor VII metabolism. Am J Clin Nutr 68: 552-560, 1998.
33. Moreno JJ and Mitjavila MT: The degree of unsaturation of dietary fatty acids and the development of atherosclerosis (review). J Nutr Biochem 14: 182-189, 2003.
34. Kirimlioglu V, Kirimlioglu H, Yilmaz S, Ozgor D, Coban S, Karadag N and Yologlu S: Effect of fish oil, olive oil, and vitamin E on liver pathology, cell proliferation, and antioxidant defense system in rats subjected to partial hepatectomy. Transplant Proc 38: 564-567, 2006.
35. Winder WW and Hardie DG: AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277: E1-E10, 1999.
36. Brooks SC III, Brooks JS, Lee WH, Lee MG and Kim SG: Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 124: 31-43, 2009.
37. Hwang JT, Park IJ, Shin JI, Lee YK, Lee SK, Baik HW, Ha J and Park OJ: Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 338: 694-699, 2005.
38. Auger C, Teissedre PL, Gerain P, Lequeux N, Bornet A, Serisier S, Besançon P, Caporiccio B, Cristol JP and Rouanet JM: Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J Agric Food Chem 53: 2015-2021, 2005.
39. Weng MS, Ho CT, Ho YS and Lin JK: Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling. Toxicol Appl Pharmacol 218: 107-118, 2007.